In particular, we demonstrated that genotoxic drugs, when used at doses that do not affect cell viability, induce the up-regulation of NKG2D and DNAM-1 ligand expression on several multiple myeloma cell lines and primary malignant plasma cells, and consequently enhance NK cell degranulation toward drug-treated tumor cells. This evidence concerns the gene CD226 and neoplasm.